|
|
|
| This article has been cited by | | 1 | Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course | | | Aneesha Haryal,Matthew J. Townsend,Vinitha Baskaran,Padmavathi Srivoleti,Anita Giobbie-Hurder,Jordan S. Sack,Raymond A. Isidro,Nicole R. LeBoeuf,Elizabeth I. Buchbinder,F. Stephen Hodi,Shilpa Grover | | Cancer.2023;129(3)367 | | [DOI] | | | 2 | Pembrolizumab | | | Aneesha Haryal,Matthew J. Townsend,Vinitha Baskaran,Padmavathi Srivoleti,Anita Giobbie-Hurder,Jordan S. Sack,Raymond A. Isidro,Nicole R. LeBoeuf,Elizabeth I. Buchbinder,F. Stephen Hodi,Shilpa Grover | | Reactions Weekly.2022;1898(1)324 | | [DOI] | | | 3 | Immune-mediated Gastritis in a Patient with metastatic Lung Cancer due to Therapy with the immune Checkpoint Inhibitor Pembrolizumab – Differences and Similarities in Comparison to “endogenous” autoimmune Type A Gastritis and a review of literature | | | Miriam Eva Ecker,Helgard Weckauf,Sandra Tebbe,Frank Schuppert | | Zeitschrift für Gastroenterologie.2023;1898(1)324 | | [DOI] | |
|
